PO-1002: Retrospective assessment of treatment planning quality in prostate SBRT  by Malisan, M.R. et al.
3rd ESTRO Forum 2015                                                                                                                                         S537 
 
   
PO-1001   
Respiratory gating reduces heart doses for proton 
radiotherapy of the breast and internal mammary chain 
S. Hackett1, F. Fiorini1, S. Petillion2, C. Taylor3, C. Weltens2, 
K. Vallis1, S. Darby3, F. Van den Heuvel1 
1University of Oxford, Department of Oncology, Oxford, 
United Kingdom  
2Universitair Ziekenhuis Leuven, Radiotherapie-Oncologie, 
Leuven, Belgium  
3University of Oxford, Clinical Trial Service Unit, Oxford, 
United Kingdom  
 
Purpose/Objective: Irradiation of the internal mammary 
chain (IMC) of lymph nodes may increase local control and 
overall survival for breast cancer. However, including the IMC 
in the treatment volume can significantly increase the doses 
to OARs, so these improvements could be outweighed by 
increased risk of late toxicities. Doses to cardiopulmonary 
volumes can be reduced for photon breast radiotherapy, even 
when IMC nodes are included in the PTV, by delivering 
treatment only during deep inspiration, but the benefits of 
respiratory gating for proton breast radiotherapy have not 
been examined. This study evaluates the doses to OARs for 
proton radiotherapy of the breast and IMC during free 
breathing (FB) and maximum inspiration (MI). 
Materials and Methods: Gated and free-breathing CT scans 
were obtained for 18 patients. The CTVs and PTVs for the IMC 
and breast, and the OARs (heart, contralateral breast and 
ipsi- and contra-lateral lung) were outlined. The PTVIMC, 
excluding the volume overlapping PTVBreast, and PTVBreast were 
prescribed doses of 40 Gy and 50 Gy respectively. 
Treatments were planned with Eclipse v13 for four proton 
fields ranging from -40° to 75° delivered via spot-scanning. 
Plans were optimised to minimise doses to the ipsilateral lung 
and heart whilst ensuring PTV coverage met the constraints 
that V95% ≥ 95% and V107% ≤ 2% of the prescribed dose. The 
homogeneity index (HI) of CTV coverage was characterised as 
(D98% - D2%)/prescribed dose. Mean doses to the OARs, V5Gy 
and V20Gy for each lung, and V5Gy and V22.5Gy for the heart were 
calculated. Dose metrics for CTVs and OARs for plans on 
paired MI and FB datasets were compared using Student's t-
tests. Doses to CTVIMC were evaluated excluding the volumes 
overlapped by PTVBreast. 
Results: All plans met the criteria for PTV coverage. Metrics 
for CTVs and OARs are shown in Table 1 and a typical dose 
distribution, including PTVBreast (red contour) and PTVIMC (blue 
contour), is shown in Figure 1. The doses to OARs differed 
significantly between paired plans, with higher doses to the 
ipsilateral lung but lower doses to the heart for gated 
compared with free-breathing plans. Homogeneity of CTV 
coverage also differed significantly, although mean CTV doses 
did not. The higher HI for CTVIMC than CTVBreast is due to the 
dose gradient at the border between PTVBreast and CTVIMC. 
 
 
 
 
Conclusions: Proton radiotherapy for breast treatments can 
achieve highly uniform target coverage whilst delivering low 
doses to OARs. Gating on the maximum inspiration phase of 
respiration has the potential to further reduce heart doses 
whilst slightly increasing doses to the ipsilateral lung. 
However, the robustness of the dose distributions to 
respiratory motion and patient positioning errors may also 
differ between free-breathing and gated treatments, and will 
be investigated in future work. 
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Purpose/Objective: In prostate SBRT the proximity to PTV of 
organs at risk represent a formidable challenge in order to 
ensure the respect of clinical dose constraints. Moreover, 
there are no objective criteria relative to the degree of 
conformity or homogeneity of dose in PTV to determine 
whether an optimal plan has been achieved, so there could 
be inter-planner differences due to the subjective judgement 
of plan’s quality. In this study, a dosimetric quality 
assessment of the first 40 clinical VMAT plans for prostate 
SBRT is presented with the goal to identify the most efficient 
quantitative metrics for plan quality evaluation and to 
improve inter-planner consistency.  
Materials and Methods: Since 2012, 40 patients at 
low/intermediate risk for localized prostate cancer have 
been planned for SBRT. Fraction size is 6 Gy for 7 fractions, 
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delivered twice a week with a VMAT technique, with 2 arcs 
using 6MV photons from a Varian iX linac. Planning was 
performed by 3 different planners in Varian Eclipse 10.0 TPS 
with the AAA algorithm. Dose prescription is the average dose 
to PTV, with the request V95% >95%. Plan quality was 
assessed using van’t Riet dose conformation number (CN95%), 
Baltas conformity index (COIN), ICRU-83 homogeneity index 
(HI), the ratio of the 50% isodose volume to PTV (R50%) to 
assess intermediate dose spillage, and compliance to protocol 
constraints. Correlation between each quality index and 
protocol compliance was performed to identify the most 
efficient ones. 
Results: The main dosimetric results are presented in the 
following table. For the PTV only the constraint for D98% is not 
met in 2 cases. As for the OARs, most dosimetric parameters 
are well within the protocol constraints, with the notable 
exception of maximal doses to rectum and bladder (D1% less 
than 95% and 100% of the prescription dose, respectively) for 
which the constraints are exceeded in about 20% of cases. 
Mean and s.d. values for CN95%, COIN, R50%, HI are 
0.90±0.05, 0.86±0.05, 3.4±0.3, 9.9%±2.2%, respectively. CN95% 
results moreover linearly correlated with both COIN and 
R50%. It increases with HI and seems to reach a plateau for HI 
about 11% (see Figure). 
 
 
 
Conclusions: Analysis has shown good coverage of PTV and 
difficulty to meet the constraints relative to the maximal 
doses of rectum and bladder when these are significantly 
included in the PTV. As for the measure of plan quality, the 
average value of CN95% is well above the 0.80 threshold, while 
its small coefficient of variation suggests a consistent 
application of the planning protocol among the different 
planners involved in the study. Due to its correlation with 
COIN and R50%, CN95% seems the most effective quantitative 
measure for plan quality in terms of target coverage, dose 
fall-off and/or general normal tissue sparing. Finally, the 
best conformity is obtained only with a given degree of dose 
inhomogeneity in the PTV.  
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Purpose/Objective: Stereotactic Ablative Body Radiotherapy 
(SABR) for vertebral metastases is an emerging treatment in 
oligometastatic solid tumor patients to achieve long-term 
symptom control and sustain quality of life. Accurate patient 
positioning is essential to avoid radiation-induced 
myelopathy. In absence of a 6D robotic couch system at the 
treatment unit, we assessed the inter- and intrafraction 
setup errors for patients positioned with and without vacuum 
mattress. 
Materials and Methods: From November 2013 until July 2014, 
9 patients with 10 vertebral metastases were treated 
consecutively with fractionated SABR (48Gy/24 fractions on 
the entire affected vertebra with an integrated boost to 
66Gy/24 fractions on the metastasis). A dedicated online 
match with the planning-CT on the spinal canal of the 
involved vertebra was performed using ConeBeam CTs 
(CBCTs) prior to every treatment fraction. CBCTs acquired 
prior to and after treatment were analyzed to respectively 
evaluate the interfraction pitch and roll setup errors and the 
intrafraction motions.  
Results: A total of 411 pre- and post SABR CBCTs were 
evaluated in 5 patients immobilized using a vacuum mattress 
and in 4 patients without immobilization device. 4 thoracic, 4 
lumbar, and 2 sacral vertebral metastases were treated. No 
acute grade ≥ 3 toxicity was observed. For the interfraction 
setup error analysis, 214 pre-treatment CBCTs were matched 
offline with planning-CTs to determine the possible pitch and 
roll. A pitch and roll setup error of ≥ 2° was observed in 35 
fractions (16%). Pitch and roll of ≥ 2° and ≥ 3° were less 
frequent in fractions treated with vs without a vacuum 
mattress: for ≥ 2°: 9% vs 26%, and for ≥ 3°: 2% vs 4%, 
respectively (p=0.04 chi-square test, Figure 1). The mean ± 
SD of absolute interfraction pitch and roll values for patients 
with and without vacuum mattress were 0.90 ± 0.61mm and 
0.90 ± 0.82 mm (non-significant, t-test), respectively.  
For the intrafraction motion analysis, a total of 197 post-
treatment CBCTs were evaluated. Intrafraction errors of ≥ 
2mm and ≥ 2° were less frequent in fractions with vs without 
a vacuum mattress (1% vs 20%, respectively; p<0.001 chi-
square test). Also, intrafraction errors >3mm and >3° were 
less frequent in fractions treated using vacuum mattress (0% 
vs 5%, respectively; p<0.001 chi-square test, Figure 1). The 
mean ± SD of absolute intrafraction motion values for 
